These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 25368259

  • 1. Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in non-small cell lung cancer cells.
    Gavrilov V, Lavrenkov K, Ariad S, Shany S.
    Anticancer Res; 2014 Nov; 34(11):6565-72. PubMed ID: 25368259
    [Abstract] [Full Text] [Related]

  • 2. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
    Shirsath N, Rathos M, Chaudhari U, Sivaramakrishnan H, Joshi K.
    Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
    [Abstract] [Full Text] [Related]

  • 3. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.
    Hubaux R, Vandermeers F, Crisanti MC, Kapoor V, Burny A, Mascaux C, Albelda SM, Willems L.
    Eur J Cancer; 2010 Jun; 46(9):1724-34. PubMed ID: 20451370
    [Abstract] [Full Text] [Related]

  • 4. Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma.
    Mack PC, Gandara DR, Lau AH, Lara PN, Edelman MJ, Gumerlock PH.
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):337-48. PubMed ID: 12721762
    [Abstract] [Full Text] [Related]

  • 5. A combined pretreatment of 1,25-dihydroxyvitamin D3 and sodium valproate enhances the damaging effect of ionizing radiation on prostate cancer cells.
    Gavrilov V, Leibovich Y, Ariad S, Lavrenkov K, Shany S.
    J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):391-4. PubMed ID: 20214985
    [Abstract] [Full Text] [Related]

  • 6. TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer.
    Zhu K, Fang W, Chen Y, Lin S, Chen X.
    Oncol Rep; 2014 Sep; 32(3):1234-42. PubMed ID: 25017445
    [Abstract] [Full Text] [Related]

  • 7. Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: a multi-center phase II study.
    Juan O, Sánchez-Hernández A, Vázquez S, Casal J, Firvida JL, Aparisi F, Muñoz J, García-Sánchez J, Gironés R, Lázaro M, Giner V.
    Anticancer Res; 2014 Apr; 34(4):1959-66. PubMed ID: 24692732
    [Abstract] [Full Text] [Related]

  • 8. Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation.
    Seo SK, Jin HO, Woo SH, Kim YS, An S, Lee JH, Hong SI, Lee KH, Choe TB, Park IC.
    J Thorac Oncol; 2011 Aug; 6(8):1313-9. PubMed ID: 21642861
    [Abstract] [Full Text] [Related]

  • 9. The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells.
    Groh T, Hrabeta J, Khalil MA, Doktorova H, Eckschlager T, Stiborova M.
    Int J Oncol; 2015 Jul; 47(1):343-52. PubMed ID: 25963435
    [Abstract] [Full Text] [Related]

  • 10. Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): a feasibility study.
    Beckmann G, Fietkau R, Huber RM, Kleine P, Schmidt M, Semrau S, Aubert D, Fittipaldo A, Flentje M.
    Onkologie; 2006 Apr; 29(4):137-42. PubMed ID: 16601369
    [Abstract] [Full Text] [Related]

  • 11. Valproic acid (VPA) enhances cisplatin sensitivity of non-small cell lung cancer cells via HDAC2 mediated down regulation of ABCA1.
    Chen JH, Zheng YL, Xu CQ, Gu LZ, Ding ZL, Qin L, Wang Y, Fu R, Wan YF, Hu CP.
    Biol Chem; 2017 Jun 27; 398(7):785-792. PubMed ID: 28002023
    [Abstract] [Full Text] [Related]

  • 12. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells.
    Zhou Y, Pan DS, Shan S, Zhu JZ, Zhang K, Yue XP, Nie LP, Wan J, Lu XP, Zhang W, Ning ZQ.
    Biomed Pharmacother; 2014 May 27; 68(4):483-91. PubMed ID: 24721323
    [Abstract] [Full Text] [Related]

  • 13. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
    Lena MD, Ramlau R, Hansen O, Lorusso V, Wagner L, Barni S, Cristovao MM, Huber R, Alberola V, Mitrovic M, Colin C, Gasmi J.
    Lung Cancer; 2005 Apr 27; 48(1):129-35. PubMed ID: 15777980
    [Abstract] [Full Text] [Related]

  • 14. The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer.
    Hirose T, Mizutani Y, Ohmori T, Ishida H, Hosaka T, Ando K, Shirai T, Okuda K, Ohnishi T, Horichi N, Kubota H, Adachi M.
    Cancer Chemother Pharmacol; 2006 Sep 27; 58(3):361-7. PubMed ID: 16331494
    [Abstract] [Full Text] [Related]

  • 15. Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.
    Groh T, Hrabeta J, Poljakova J, Eckschlager T, Stiborova M.
    Neuro Endocrinol Lett; 2012 Sep 27; 33 Suppl 3():16-24. PubMed ID: 23353839
    [Abstract] [Full Text] [Related]

  • 16. A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).
    Wakelee HA, Middleton G, Dunlop D, Ramlau R, Leighl N, Hao D, Lopez-Anaya A, Zatloukal P, Jacobs CD.
    Cancer Chemother Pharmacol; 2012 Mar 27; 69(3):815-24. PubMed ID: 22057854
    [Abstract] [Full Text] [Related]

  • 17. Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.
    Wawruszak A, Luszczki JJ, Grabarska A, Gumbarewicz E, Dmoszynska-Graniczka M, Polberg K, Stepulak A.
    PLoS One; 2015 Mar 27; 10(11):e0143013. PubMed ID: 26580554
    [Abstract] [Full Text] [Related]

  • 18. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
    Karthik S, Sankar R, Varunkumar K, Ravikumar V.
    Biomed Pharmacother; 2014 Apr 27; 68(3):327-34. PubMed ID: 24485799
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401.
    Takayama K, Inoue K, Tokunaga S, Matsumoto T, Oshima T, Kawasaki M, Imanaga T, Kuba M, Takeshita M, Harada T, Shioyama Y, Nakanishi Y.
    Cancer Chemother Pharmacol; 2013 Dec 27; 72(6):1353-9. PubMed ID: 24166107
    [Abstract] [Full Text] [Related]

  • 20. Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.
    Zuco V, Cassinelli G, Cossa G, Gatti L, Favini E, Tortoreto M, Cominetti D, Scanziani E, Castiglioni V, Cincinelli R, Giannini G, Zunino F, Zaffaroni N, Lanzi C, Perego P.
    Biochem Pharmacol; 2015 Mar 15; 94(2):79-90. PubMed ID: 25600908
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.